Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...
Päätekijät: | Sun Joo Cha, Kiyoung Kim |
---|---|
Aineistotyyppi: | Artikkeli |
Kieli: | English |
Julkaistu: |
MDPI AG
2022-01-01
|
Sarja: | Antioxidants |
Aiheet: | |
Linkit: | https://www.mdpi.com/2076-3921/11/2/195 |
Samankaltaisia teoksia
-
A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
Tekijä: Erdi Şahin
Julkaistu: (2018-03-01) -
Edaravone: A new hope for patients with amyotrophic lateral sclerosis
Tekijä: Shivangi Garg, et al.
Julkaistu: (2019-01-01) -
Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
Tekijä: Hideki Houzen, et al.
Julkaistu: (2021-07-01) -
Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
Tekijä: Jin-Mo Park, et al.
Julkaistu: (2022-07-01) -
Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
Tekijä: Chang Liu, et al.
Julkaistu: (2024-10-01)